Texas Abortion Pill Ruling Could Undermine US Drug Regulator
A federal judge's decision to suspend FDA approval of abortion pill mifepristone could severely weaken the agency if allowed to stand, health policy and legal experts have said.
Stay updated with breaking news from Goodwin Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A federal judge's decision to suspend FDA approval of abortion pill mifepristone could severely weaken the agency if allowed to stand, health policy and legal experts have said.
The U.S. FDA approved mifepristone, part of a two-drug regimen that accounts for more than half of U.S. abortions, over 20 years ago.
A federal judge in Texas could soon order the U.S. Food and Drug Administration to withdraw its approval of abortion pill mifepristone, a move that if allowed to stand could severely undermine the agency, health policy and legal experts said. The closely followed case could potentially lead to a nationwide ban on mifepristone — part…
A federal judge in Texas could soon order the U.S. Food and Drug Administration to withdraw its approval of abortion pill mifepristone, a move that if allowed to stand could severely undermine the agency, health policy and legal experts said.
The closely followed case could potentially lead to a nationwide ban on mifepristone — part of a two-drug regimen that accounts for more than half of U.S. abortions — and call into question the FDA's power to regulate all drugs nationwide, they said